HK1155644A1 - 結合抗腫瘤療法 - Google Patents

結合抗腫瘤療法

Info

Publication number
HK1155644A1
HK1155644A1 HK11109854.3A HK11109854A HK1155644A1 HK 1155644 A1 HK1155644 A1 HK 1155644A1 HK 11109854 A HK11109854 A HK 11109854A HK 1155644 A1 HK1155644 A1 HK 1155644A1
Authority
HK
Hong Kong
Prior art keywords
antitumor therapy
combination antitumor
combination
therapy
antitumor
Prior art date
Application number
HK11109854.3A
Other languages
English (en)
Inventor
Jeffery L Keene
Dennis P Riley
Robert A Beardsley
Original Assignee
Galera Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galera Therapeutics Llc filed Critical Galera Therapeutics Llc
Publication of HK1155644A1 publication Critical patent/HK1155644A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11109854.3A 2008-05-22 2011-09-19 結合抗腫瘤療法 HK1155644A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5541808P 2008-05-22 2008-05-22
PCT/US2009/045029 WO2009143454A2 (en) 2008-05-22 2009-05-22 Combination antitumor therapy

Publications (1)

Publication Number Publication Date
HK1155644A1 true HK1155644A1 (zh) 2012-05-25

Family

ID=41340927

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11109854.3A HK1155644A1 (zh) 2008-05-22 2011-09-19 結合抗腫瘤療法

Country Status (6)

Country Link
US (1) US9198893B2 (zh)
EP (2) EP2296645B1 (zh)
CA (1) CA2724550C (zh)
ES (1) ES2530462T3 (zh)
HK (1) HK1155644A1 (zh)
WO (1) WO2009143454A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2056675T (pt) 2006-10-12 2019-05-09 Galera Labs Llc Métodos de tratamento da mucosite oral
EP2760874A4 (en) 2011-09-26 2015-04-08 Galera Therapeutics Llc METHOD FOR THE TREATMENT OF ILLNESSES
US9446064B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
AU2015301746A1 (en) * 2014-08-13 2017-02-16 Celgene Corporation Combination therapy for treating cancer
US20190083521A1 (en) * 2014-09-17 2019-03-21 Epizyme, Inc. Combination therapy for treating cancer
EA201890471A1 (ru) * 2015-08-11 2018-10-31 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комплексные соединения, содержащие макроциклическое кольцо пентаазы, обладающие пероральной биодоступностью
BR112018072560A2 (pt) * 2016-05-03 2019-02-19 Galera Labs, Llc terapia de combinação para tratamento do câncer
CN109906081A (zh) * 2016-09-01 2019-06-18 加莱拉实验室有限责任公司 利用五氮杂大环络合物和抗坏血酸类化合物的联合癌症疗法
US20210361701A1 (en) * 2017-02-15 2021-11-25 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local delivery
IL305082A (en) * 2017-04-13 2023-10-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
EP3388082A1 (en) * 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
AU2019215032A1 (en) * 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
JP2019131508A (ja) * 2018-01-31 2019-08-08 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
JP2023536389A (ja) * 2020-06-02 2023-08-25 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー ペンタアザ大環状環複合体およびホルモン療法剤の併用がん治療法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184365B1 (en) 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
TW197439B (zh) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5440056A (en) 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
CA2136213A1 (en) 1992-05-21 1993-11-25 Richard N. Arteca Cultured taxu tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5976498A (en) 1995-08-17 1999-11-02 Neumann; William L. Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
AU3740997A (en) 1996-08-26 1998-03-19 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
AU4966597A (en) 1996-11-19 1998-06-10 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
HUP0002521A3 (en) 1997-06-20 2002-04-29 Baker Norton Pharma Onium salts of paclitaxel, process for producing them and medicaments comprising the same
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
PT2056675T (pt) * 2006-10-12 2019-05-09 Galera Labs Llc Métodos de tratamento da mucosite oral

Also Published As

Publication number Publication date
EP2859916A2 (en) 2015-04-15
US20110136756A1 (en) 2011-06-09
WO2009143454A2 (en) 2009-11-26
ES2530462T3 (es) 2015-03-03
EP2296645A2 (en) 2011-03-23
CA2724550C (en) 2017-01-03
US9198893B2 (en) 2015-12-01
CA2724550A1 (en) 2009-11-26
EP2296645B1 (en) 2014-11-19
EP2296645A4 (en) 2012-03-07
EP2859916B1 (en) 2017-11-29
EP2859916A3 (en) 2015-04-29
WO2009143454A3 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
IL206654A0 (en) Combination therapy
HK1155644A1 (zh) 結合抗腫瘤療法
IL199992A0 (en) Combination therapy
IL208351A0 (en) Antiviral therapy
EP2283862A4 (en) CANCER AGENT
GB0719518D0 (en) Therapy
SI2147122T1 (sl) Encimatska terapija proti raku
EP2211863A4 (en) COMBINATION THERAPY
EP2309854A4 (en) ACCELERATED THERAPY:
IL208001A0 (en) Improved anticancer treatments
GB0700284D0 (en) Combination therapy
GB0803948D0 (en) Combination therapy
GB0916997D0 (en) Combination therapy
GB0809046D0 (en) Cancer treatment
GB0907973D0 (en) Combination therapy
GB0716072D0 (en) Therapy
GB0700635D0 (en) Therapy
GB0809856D0 (en) Anti-cancer combination therapy
GB0813292D0 (en) Therapy
GB0812659D0 (en) Therapy
GB0808841D0 (en) Novel anti-cancer combination therapy
GB0819857D0 (en) Antiviral therapy
GB0703963D0 (en) Therapy
GB0705917D0 (en) Therapy
GB0819644D0 (en) New therapy